Analysts Offer Predictions for CRNX FY2026 Earnings

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) - Analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for Crinetics Pharmaceuticals in a note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst J. Schimmer expects that the company will earn ($4.87) per share for the year. The consensus estimate for Crinetics Pharmaceuticals' current full-year earnings is ($3.73) per share.

Separately, Stifel Nicolaus started coverage on shares of Crinetics Pharmaceuticals in a research note on Tuesday, March 25th. They set a "buy" rating and a $60.00 target price for the company. One research analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $74.56.

Crinetics Pharmaceuticals Trading Down 1.2%

NASDAQ:CRNX traded down $0.40 during mid-day trading on Tuesday, reaching $31.77. 557,240 shares of the stock were exchanged, compared to its average volume of 846,245. The business has a fifty day moving average price of $31.12 and a 200 day moving average price of $38.07. Crinetics Pharmaceuticals has a 1-year low of $24.10 and a 1-year high of $62.53. The firm has a market capitalization of $2.97 billion, a PE ratio of -8.52 and a beta of 0.28.

Crinetics Pharmaceuticals (NASDAQ:CRNX - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($1.04) EPS for the quarter, missing analysts' consensus estimates of ($0.99) by ($0.05). The firm had revenue of $0.36 million during the quarter, compared to the consensus estimate of $0.10 million. The business's quarterly revenue was down 43.6% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.93) earnings per share.

Insider Activity at Crinetics Pharmaceuticals

In other Crinetics Pharmaceuticals news, COO Jeff E. Knight sold 7,162 shares of Crinetics Pharmaceuticals stock in a transaction dated Wednesday, March 19th. The stock was sold at an average price of $34.20, for a total transaction of $244,940.40. Following the transaction, the chief operating officer now owns 87,491 shares of the company's stock, valued at $2,992,192.20. The trade was a 7.57% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Richard Scott Struthers sold 17,338 shares of the stock in a transaction that occurred on Wednesday, March 19th. The stock was sold at an average price of $34.20, for a total transaction of $592,959.60. Following the completion of the sale, the chief executive officer now directly owns 329,147 shares of the company's stock, valued at $11,256,827.40. This trade represents a 5.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 27,015 shares of company stock valued at $923,913. Company insiders own 4.60% of the company's stock.

Institutional Investors Weigh In On Crinetics Pharmaceuticals

A number of institutional investors have recently modified their holdings of the stock. KBC Group NV raised its holdings in shares of Crinetics Pharmaceuticals by 10.0% during the first quarter. KBC Group NV now owns 4,082 shares of the company's stock worth $137,000 after acquiring an additional 370 shares in the last quarter. MetLife Investment Management LLC increased its position in Crinetics Pharmaceuticals by 0.7% in the 1st quarter. MetLife Investment Management LLC now owns 53,414 shares of the company's stock worth $1,792,000 after purchasing an additional 394 shares during the last quarter. Martingale Asset Management L P raised its stake in shares of Crinetics Pharmaceuticals by 1.9% during the 4th quarter. Martingale Asset Management L P now owns 22,484 shares of the company's stock worth $1,150,000 after purchasing an additional 410 shares in the last quarter. GF Fund Management CO. LTD. lifted its holdings in shares of Crinetics Pharmaceuticals by 22.0% during the 1st quarter. GF Fund Management CO. LTD. now owns 2,375 shares of the company's stock valued at $80,000 after buying an additional 428 shares during the last quarter. Finally, Arizona State Retirement System grew its stake in shares of Crinetics Pharmaceuticals by 1.8% in the 1st quarter. Arizona State Retirement System now owns 23,899 shares of the company's stock valued at $802,000 after buying an additional 430 shares in the last quarter. Institutional investors and hedge funds own 98.51% of the company's stock.

Crinetics Pharmaceuticals Company Profile

Crinetics Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors.